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Gold nanocages (AuNCs) have been shown to be a useful tool for imaging and hyperthermia therapy of 
cancer, thanks to their unique optical properties, low toxicity and facile surface functionalization. Herein, we 
use AuNCs for selective targeting of prostate cancer cells (PC3) via specific interaction between neuropeptide 
Y (NPY) receptor and three different NPY analogs conjugated to AuNCs (Figure 1). Localized surface plasmon 
band of the nanoconjugates was set around 800 nm, which is particularly promising for in vivo applications. 
Long-term stability of nanoconjugates in different media was confirmed by UV-vis and DLS studies. Active 
NPY receptor targeting was observed by confocal microscopy showing time-dependent AuNCs cellular 
uptake. Activation of ERK1/2 pathway was evaluated by Western blot to confirm the receptor-mediated 
specific interaction with PC3. Cellular uptake kinetics were compared as a function of peptide structure. 
Cytotoxicity of nanoconjugates was evaluated by MTS and Annexin V assays, confirming their safety within 
the concentration range explored. Hyperthermia studies were carried out irradiating the cells, previously 
incubated with AuNCs, with a pulsed laser at 808 nm wavelength, showing a heating enhancement from 6 to 
35 °C above the culture temperature dependent on the irradiation power (between 1.6 and 12.7 W/cm2). 
Only cells treated with AuNCs underwent morphological alterations in the cytoskeleton structure upon laser 
irradiation, leading to membrane blebbing and loss of microvilli associated to cell migration. This effect is 
particularly promising in view of possible inhibition of proliferation and invasion of cancer cells. In summary, 
our Au-peptide NCs proved to be an efficient theranostic nanosystem for targeted detection and activatable 
killing of prostate cancer cells.  
 
 
Figure 1. Schematic representation of NPYR targeting on prostate cancer cells by peptide-functionalized gold nanocages and 
subsequent hyperthermia by NIR irradiation. 
